Amplia Therapeutics Limited Stock Analysis

Amplia Pink Sheet Analysis Notes

About 22.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.6. Some equities with similar Price to Book (P/B) outperform the market in the long run. Amplia Therapeutics recorded a loss per share of 0.02. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 30th of April 2018. Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase inhibitors for oncology and chronic fibrosis in Australia. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia. Innate Immunotherapeuti is traded on OTC Exchange in the United States.The quote for Amplia Therapeutics Limited is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To learn more about Amplia Therapeutics Limited call BSc BSc at 61 2 8003 3650 or check out https://www.ampliatx.com.

Amplia Therapeutics Investment Alerts

Amplia Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 12.13 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Amplia Therapeutics's market, we take the total number of its shares issued and multiply it by Amplia Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Amplia Profitablity

The company has Profit Margin (PM) of (1.75) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.75) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.75.

Technical Drivers

As of the 25th of November, Amplia Therapeutics shows the Downside Deviation of 21.19, risk adjusted performance of 0.0445, and Mean Deviation of 9.47. Amplia Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Amplia Therapeutics treynor ratio, as well as the relationship between the downside variance and kurtosis to decide if Amplia Therapeutics is priced correctly, providing market reflects its regular price of 0.059 per share. As Amplia Therapeutics appears to be a penny stock we also recommend to validate its total risk alpha numbers.

Amplia Therapeutics Price Movement Analysis

Amplia Therapeutics Predictive Daily Indicators

Amplia Therapeutics Forecast Models

Amplia Therapeutics' time-series forecasting models are one of many Amplia Therapeutics' pink sheet analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Amplia Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Amplia Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Amplia shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Amplia Therapeutics. By using and applying Amplia Pink Sheet analysis, traders can create a robust methodology for identifying Amplia entry and exit points for their positions.

When running Amplia Therapeutics' price analysis, check to measure Amplia Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amplia Therapeutics is operating at the current time. Most of Amplia Therapeutics' value examination focuses on studying past and present price action to predict the probability of Amplia Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amplia Therapeutics' price. Additionally, you may evaluate how the addition of Amplia Therapeutics to your portfolios can decrease your overall portfolio volatility.